| Company Name | Novartis |
|---|---|
| Protocol Number | CLTW888A12401 |
| Title of Study | A Post-Authorization, Multicenter, Multinational, Longitudinal, Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec |
| Primary Objective | The objective of this registry-based study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products. |
| Number of Sites | 1 |
| Period of Study | From：01/Mar/2024 to：30/Jun/2030 |
| Number of Patients | 40人 |
| IRB Approval Date | |
| Publication Plan / Date | NA |
